{
    "ticker": "ANNX",
    "name": "Annovis Bio, Inc.",
    "description": "Annovis Bio, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. Founded in 2016, the company is headquartered in Berwyn, Pennsylvania. Annovis Bio aims to address the urgent need for effective treatments for conditions such as Alzheimer's disease and Parkinson's disease. Their lead product candidate, ANVS401, is a small molecule that is designed to target neuroinflammation and restore neuronal function. By inhibiting the activity of specific proteins involved in the neurodegenerative process, Annovis Bio is working to halt or reverse the progression of these debilitating diseases. The company is committed to advancing its clinical trials and aims to bring its innovative therapies to market to improve the quality of life for patients suffering from neurodegenerative disorders. Through rigorous research and collaboration with leading scientists, Annovis Bio seeks to transform the treatment landscape for these challenging conditions, providing hope for patients and their families. With a strong pipeline of drug candidates and ongoing clinical studies, Annovis Bio is positioned to make significant contributions to the field of neurology and to enhance patient outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Berwyn, Pennsylvania, USA",
    "founded": "2016",
    "website": "https://www.annovisbio.com",
    "ceo": "Maria L. Maccecchini",
    "social_media": {
        "twitter": "https://twitter.com/annovisbio",
        "linkedin": "https://www.linkedin.com/company/annovis-bio-inc"
    },
    "investor_relations": "https://www.annovisbio.com/investor-relations",
    "key_executives": [
        {
            "name": "Maria L. Maccecchini",
            "position": "CEO"
        },
        {
            "name": "Richard A. D. G. B. R. H. D. B. R. H. D. B. R. H. D. B. R. H.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "ANVS401"
            ]
        }
    ],
    "seo": {
        "meta_title": "Annovis Bio, Inc. | Innovative Therapies for Neurodegenerative Diseases",
        "meta_description": "Learn about Annovis Bio, Inc., a biotechnology company focused on developing therapies for Alzheimer's and Parkinson's diseases. Discover their innovative approach and product pipeline.",
        "keywords": [
            "Annovis Bio",
            "Neurodegenerative Diseases",
            "Alzheimer's Disease",
            "Parkinson's Disease",
            "ANVS401"
        ]
    },
    "faq": [
        {
            "question": "What does Annovis Bio focus on?",
            "answer": "Annovis Bio focuses on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's."
        },
        {
            "question": "Who is the CEO of Annovis Bio?",
            "answer": "Maria L. Maccecchini is the CEO of Annovis Bio, Inc."
        },
        {
            "question": "Where is Annovis Bio headquartered?",
            "answer": "Annovis Bio is headquartered in Berwyn, Pennsylvania, USA."
        },
        {
            "question": "What is Annovis Bio's lead product candidate?",
            "answer": "The lead product candidate of Annovis Bio is ANVS401, aimed at treating neurodegenerative diseases."
        },
        {
            "question": "When was Annovis Bio founded?",
            "answer": "Annovis Bio was founded in 2016."
        }
    ],
    "competitors": [
        "BIIB",
        "ACAD",
        "VRTX",
        "SAVA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}